Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ulcerative pyoderma gangrenosum is a rare disease with ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...